Success Metrics

Clinical Success Rate
61.1%

Based on 11 completed trials

Completion Rate
61%(11/18)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
7(39%)

Phase Distribution

Ph phase_2
4
22%
Ph phase_1
1
6%
Ph phase_3
13
72%

Phase Distribution

1

Early Stage

4

Mid Stage

13

Late Stage

Phase Distribution18 total trials
Phase 1Safety & dosage
1(5.6%)
Phase 2Efficacy & side effects
4(22.2%)
Phase 3Large-scale testing
13(72.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

61.1%

11 of 18 finished

Non-Completion Rate

38.9%

7 ended early

Currently Active

0

trials recruiting

Total Trials

18

all time

Status Distribution
Completed(11)
Terminated(7)

Detailed Status

Completed11
Terminated7

Development Timeline

Analytics

Development Status

Total Trials
18
Active
0
Success Rate
61.1%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (5.6%)
Phase 24 (22.2%)
Phase 313 (72.2%)

Trials by Status

terminated739%
completed1161%

Recent Activity

0 active trials
Showing 5 of 18
terminatedphase_3

Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

NCT00160147
completedphase_2

Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

NCT00139906
completedphase_2

Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

NCT00139919
completedphase_3

Bifeprunox in the Treatment of Schizophrenia

NCT00193713
completedphase_2

PK Effects of Bifeprunox & Valproate in Bipolar I

NCT00141505
View all 18 trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT00160147Phase 3

Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type

Terminated
NCT00139906Phase 2

Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia

Completed
NCT00139919Phase 2

Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder

Completed
NCT00193713Phase 3

Bifeprunox in the Treatment of Schizophrenia

Completed
NCT00141505Phase 2

PK Effects of Bifeprunox & Valproate in Bipolar I

Completed
NCT00141479Phase 2

To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox

Completed
NCT00861497Phase 3

Bifeprunox Extension to Extension Study in Patients With Schizophrenia

Terminated
NCT00230828Phase 3

Patient-reported Outcomes in the Treatment of Schizophrenia

Completed
NCT00134459Phase 3

Study Evaluating Bifeprunox in Bipolar Depression

Completed
NCT00366327Phase 3

Study Evaluating Bifeprunox in Patients With Schizophrenia.

Terminated
NCT00366704Phase 3

Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint

Terminated
NCT00704509Phase 3

Efficacy of Bifeprunox in Patients With Schizophrenia

Terminated
NCT00658645Phase 3

Efficacy of Bifeprunox in Patients With Schizophrenia

Terminated
NCT00581451Phase 1

Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects

Completed
NCT00396214Phase 3

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

Terminated
NCT00193687Phase 3

Bifeprunox in the Treatment of Schizophrenia

Completed
NCT00366171Phase 3

Open Label Extension Study of Bifeprunox

Completed
NCT00245973Phase 3

Study Evaluating Bifeprunox in Bipolar Depression

Completed

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18